The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

Gross, David J.; Munter, Gabriel; Bitan, Menachem; Siegal, Tali; Gabizón, Alberto; Weitzen, Ronny; Merimsky, Ofer; Ackerstein, Aliza; Salmon, Asher; Sella, Avishai; Slavin, Shimon

doi:10.1677/erc.1.01124

Cited by 135 publications

(72 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[29][30][31][32][33][34] The tumor response in our study compares favorably with the results obtained with these novel therapies. Nonetheless, the poor overall survival rates in our study confirm the poor prognosis for patients with advanced adrenocortical carcinoma and the need for improved treatment options.…”

Section: Discussionsupporting

confidence: 67%

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Fassnacht¹,

Terzolo²,

Allolio³

et al. 2012

N Engl J Med

706

502

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 67%

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Fassnacht¹,

Terzolo²,

Allolio³

et al. 2012

N Engl J Med

706

502

View full text Add to dashboard Cite

“…No remission of the tumour was observed. In another preliminary phase 2 study using imatinib mesylate in 15 patients with advanced endocrine tumours, disease progression was seen in four out of six patients with MTC (19).…”

Section: Discussionmentioning

confidence: 97%

Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma

Frank‐Raue¹,

Fabel

Delorme

et al. 2007

eur j endocrinol

View full text Add to dashboard Cite

Objective: Medullary thyroid carcinoma (MTC) is often associated with gain-of-function mutations in the RET proto-oncogene, which is found in all hereditary cases and most sporadic cases. The activated RET receptor tyrosine kinase can be inhibited by tyrosine kinase inhibitors in vitro. We evaluated the efficacy of treatment with imatinib mesylate, a tyrosine kinase inhibitor, in patients with advanced MTC. Design and patients:In this open-label clinical trial, nine patients, eight with sporadic and one with hereditary MTC, with unresectable, measurable, progressive metastases were treated with imatinib mesylate 600 mg daily. The tumour response to imatinib was evaluated after 3, 6 and 12 months by computed tomography and after 1 month by 18 F-fluoro-2-deoxy D-glucose position-emission tomographic scanning. The median duration of therapy was 8 months.Results: Overall, stable disease occurred in five patients for up to 6 months and in one patient for up to 12 months, with a median duration of progression-free survival of 6 months. Four patients had progressive disease after 12 months. One patient stopped therapy after 2 weeks because of worsening of diarrhoea. Therapy was well tolerated, although transient mild-to-moderate nausea (nZ3), oedema (nZ3), diarrhoea (nZ2) and skin rash (nZ2) were observed. Conclusion: Imatinib mesylate is well tolerated, no tumour remission was observed, only transient stable disease was achieved in some patients with advanced MTC.European Journal of Endocrinology 157 215-220

show abstract

“…Although a biochemical response of 40% and radiological response of 33% were achieved, significant lymphopenia occurred in a large number of patients, with opportunistic infections occurring in 10% [154]. More specific targeted therapy with imatinib mesylate [155] and everolimus [131] has been tried in a small number of patients with malignant pheochromocytomas; however, no significant effect was observed. Overexpression of the protein HSP-90 in malignant pheochromocytoma makes this a target of interest.…”

Section: Management Of Malignant Diseasementioning

confidence: 99%

Pheochromocytoma: Current Approaches and Future Directions

et al. 2008

View full text Add to dashboard Cite

After completing this course, the reader should be able to:1. Use current practice methods in the diagnosis of pheochromocytomas.2. Employ current practice methods in the treatment of pheochromocytomas.3. Evaluate the current molecular research that contributes to the treatment of pheochromocytomas.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTPheochromocytomas are rare catecholamine-secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra-adrenal sites. Because of the excess secretion of hormones, these tumors often cause debilitating symptoms and a poor quality of life. While medical management plays a significant role in the treatment of pheochromocytoma patients, surgical excision remains the only cure. Improved medical management and surgical techniques and an increased understanding of hereditary disease have improved the outcome of pheochromocytoma patients with benign disease; however, the outcome of patients with malignant disease remains poor. In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease. The Oncologist

show abstract

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

Abstract: Imatinib mesylate (IM), a small molecule that is a selective inhibitor of the ABL, platelet derived growth factor receptor (PDGFR-R) and stem cell ligand receptor (c-kit) tyrosine kinases

Cited by 135 publications

References 19 publications

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma

Pheochromocytoma: Current Approaches and Future Directions

Contact Info

Product

Resources

About